Subscribe to Search results

The merits and drawbacks of NANBH surrogate screening were discussed in an editorial in The Lancet.

Published on:

At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Brian McClelland would produce an outline study protocol, which might include non-specific markers like ALT level and/or the presence of anti-HBc in donors.

Published on:

At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Gunson would ask the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.

Published on:

Dr Gunson asked the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.

Published on:

The MRC sought further information on Dr Gunson's request on samples from the 1974 UK prospective study on transfusion associated hepatitis, including where Dr Gunson believed the samples might be held.

Published on:

Dr Brian McClelland outlined two options for the 1974 UK prospective hepatitis study and suggested that a multi-centre study of this type would cost between £250,000 and £500,000.

Published on:

Dr Brian McClelland contacted Dr James regarding an abstract of prospective study on possible non-A non-B post-transfusion and the availability of samples from their study.

Published on:

Dr James expressed a willingness to collaborate with the Working Party on providing samples from their earlier study while noting he and his colleagues wished to avoid defrosting and refreezing their stored sera on too many occasions.

Published on:

Dr Gunson stated in a letter to Dr Keith Gibson that unless they were able to obtain data relating to the situation within the UK, they may be placed in the position of taking up a test, for medico-legal considerations if nothing else, developed abroad where the incidence or characteristics of the illness differs from that in the UK and such a decision could cost the NHS millions each year.

Published on:

Dr Gibson of the MRC informed Dr Gunson that many of the samples from the previous MRC study had been lost as a result of power failures, an audit of what was left would be carried.

Published on:

Professor Zuckerman informed Dr Gibson that a duplicate set of samples had been disposed of.

Published on:

Dr Gunson told the Working Party on Transfusion Associated Hepatitis that many of the samples from his previous MRC study had been lost due to a power failure. The Working Party acknowledged that this ruled out the chance of updating the testing of samples from that study with modern diagnostic assays.

Published on:

The Working Party on Transfusion Associated Hepatitis noted that no source of funding had been found to date for Dr Brian McClelland's proposed study.

Published on:

The Working Party on Transfusion Associated Hepatitis discussed the possibility of seeking funding from the MRC for a joint study involving Edinburgh and the North London Blood Transfusion Centre. Dr John Barbara planned to speak to the Director and submit a draft proposal.

Published on:

The Working Party on Transfusion Associated Hepatitis discussed potential requests to Dr James of the Freeman Hospital for access to samples from his prospective study of 248 patients who had undergone cardiac surgery.

Published on:

Dr James and his colleagues published the results of a study on post-transfusion hepatitis after cardiac surgery which suggested that NANBH after blood transfusion "from a largely British blood donor group probably leads to clinically significant chronic liver disease very rarely indeed."

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland stated that he never saw a follow-up proposal from Dr Barbara in relation to a joint study involving Edinburgh and the North London Blood Transfusion Centre.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland described the transfusion service as "losing sight of" NANBH for several years from 1983 due to preoccupation with HIV/AIDS.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland explained that ALT levels was only a small element of his proposal for a comprehensive study.

Published on:

In oral evidence to the Inquiry, Dr Brian McClelland accepted that nothing had really moved on since the beginning of the 1980s in relation to NANBH surrogate screening study.

Published on: